

Serum Antibodies for Diagnosis of Inflammatory Bowel Disease

Date of Origin: 07/2003

Last Review Date: 06/26/2024

Effective Date: 07/01/2024

Dates Reviewed: 07/2004, 06/2005, 05/2006, 06/2007, 07/2008, 01/2010, 07/2011, 06/2012, 05/2013, 04/2014, 04/2015, 05/2016, 05/2017, 05/2018, 04/2019, 11/2019, 07/2020, 07/2021, 06/2022, 07/2023, 06/2024

Developed By: Medical Necessity Criteria Committee

I. Description

Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory intestinal condition that can be subdivided into ulcerative colitis (UC) and Crohn's disease (CD). Patients with IBD may have a wide variety of symptoms including diarrhea, abdominal pain, and rectal bleeding. Diagnosis is established by a combination of radiographic, endoscopic, and histologic work-up. However, in approximately 10% of patients with IBD, the distinction between ulcerative colitis and Crohn's disease cannot be made with certainty and the diagnosis becomes "indeterminate colitis." Two serum antibodies, anti-neutrophilic cytoplasmic antibody (ANCA) and anti-saccharomyces cerevisiae (ASCA) have been investigated as a technique to improve the efficiency and accuracy of diagnosing IBD. ANCA has been detected in UC patients 50-80%, and less frequently in CD patients, 10-40%. ASCA has been detected in 46-70% of patients with Crohn's disease and 6-12% of patients with ulcerative colitis. These non-invasive tests examine serological panels of antibodies, including ASCA and ANCA, to diagnose IBD and differentiate between UC and CD. However, research has determined that there is insufficient sensitivity to diagnose ulcerative colitis or Crohn's disease.

Genetic polymorphisms for thiopurine methyltransferase (TPMT), the primary enzyme-metabolizing azathiopurine and 6-mercaptopurine, have been identified to assist in regulating therapy according to the measurements of azathiopurine/6-mercaptopurine metabolites. Current recommendations from the FDA include determination of TPMT (either enzyme or genotype) prior to initiating treatment with azathiopurine or 6-mercaptopurine. Tests were developed by Prometheus® (and other labs have followed) to provide guidance in determining therapeutic direction and predicting therapeutic response in individual patients receiving treatment with Infliximab (IFX), vedolizumab (VDZ), or Adalimumab (ADA). The Thiopurine metabolite test is used during treatment for the ongoing evaluation of patient response to thiopurine therapies.

The tests may be performed by other laboratories besides Prometheus® but the medical criteria below apply regardless of the requesting laboratory.

II. Criteria: CWQI HCS-0061

- A. Summit Health considers baseline TPMT genotype testing medically necessary in individuals with inflammatory bowel disease, for any of the following: *****Note – this test is covered for these indications one time during the patient’s lifetime*****
 - a. To determine candidacy for thiopurine treatment prior to initiation of 6-Mercaptopurine (6-MP), or Azathiopurine (AZA), or thioguanine (6-TG)
 - b. In patients on thiopurine therapy with abnormal CBC results that do not respond to dose reduction
- B. Monitoring of thiopurine metabolite levels in individuals with inflammatory bowel disease is considered medically necessary for either of the following indications:
 - a. To measure blood levels in individuals suspected of having toxic responses to AZA and/or 6-MP (e.g., hepatotoxicity or myelotoxicity)
 - b. To measure drug levels in individuals who have not responded
- C. TPMT gene mutation assays and TPMT phenotypic assays are considered experimental and investigational for all other indications because their effectiveness for indications other than the one listed above has not been established.
- D. Analysis of the metabolite markers of azathioprine and 6-mercaptopurine, including 6-methylmercaptopurine ribonucleotides (6-MMRP) and 6-thioguanine nucleotides (6-TGN), is considered E and I in all other situations
- E. The following tests are considered experimental, investigational, or unproven to diagnose IBD, to distinguish UC from Crohn's, to manage IBD, and for all other indications because their effectiveness has not been established:
 - a. ASCA - anti-Saccharomyces cerevisiae antibodies
 - b. ANCA - anti-neutrophil cytoplasmic antibodies
 - c. ACCA - anti-chitobioside carbohydrate antibodies
 - d. ALCA - anti-laminaribioside carbohydrate antibodies
 - e. AMCA - anti-mannobioside carbohydrate antibodies
 - f. Anti-C - anti-chitin IgA
 - g. Anti-L - anti-laminarin IgA
 - h. OmpC - anti-outer membrane porin C antibodies
 - i. anti-CBir1 - anti-CBir1 flagellin antibodies
 - j. 12 antibodies
 - k. Prometheus IBD sgi diagnostic test
- F. Anti-smooth muscle antibodies (ASMA) is considered experimental and investigational to diagnose inflammatory bowel disease or to distinguish ulcerative colitis from Crohn's disease because its effectiveness for these indications has not been established. *****Note: ASMA may be medically necessary to diagnose autoimmune hepatitis*****
- G. Fecal lactoferrin is considered medically necessary for distinguishing inflammatory bowel disease (Crohn’s disease, ulcerative colitis) from irritable bowel syndrome
- H. Fecal lactoferrin is considered experimental or investigational for evaluation of infectious diarrhea, Clostridium difficile infection, and all other indications
- I. Measurement of antibodies to any/all of the following, either alone or as a combination test is considered experimental or investigational
 - a. Infliximab (Remicade)

- b. Humira (adalimumab)
 - c. Entyvio (vedolizumab)
 - d. Stelara (ustekinumab)
- J. In an individual receiving treatment with any medications, measurement of serum levels of any of the following, either alone or as a combination test is considered experimental or investigational
- a. Infliximab (Remicade)
 - b. Humira (adalimumab)
 - c. Entyvio (vedolizumab)
 - d. Stelara (ustekinumab)
- K. Tests that are considered experimental or investigational for measurement of antibodies and/or serum levels include, but are not limited to:
- a. Anser IFX (Remicade/infliximab),
 - b. Anser ADA (Humira/adalimumab),
 - c. Anser VDZ (Entyvio/vedolizumab),
 - d. Anser UST (Stelara/ustekinumab)

III. Information Submitted with the Prior Authorization Request:

1. Chart notes and history and physical from ordering specialist
2. Results of colonoscopy and other diagnostic studies performed
3. Pathology report

IV. CPT or HCPC codes covered:

Codes	Description
TPMT	
81401	TPMT genetics (Molecular pathology procedure, Level 2 (eg, 2-10 SNPs, 1 methylated variant, or 1 somatic variant [typically using nonsequencing target variant analysis], or detection of a dynamic mutation disorder/triplet repeat)
81335	TPMT (thiopurine S-methyltransferase) (e.g., drug metabolism), gene analysis, common variants (e.g., *2, *3)
82657	Enzyme activity in blood cells, cultured cells, or tissue, not elsewhere specified; nonradioactive substrate, each specimen
6-thioguanine nucleotide (6-TGN) and 6-methylmercaptopurine nucleotide (6-MMPN)	
Lactoferrin, Fecal	
No specific code	Firmicutes and Bacteroidetes (F/B) ratio stool test, measurements of DNA, mRNA and protein biomarkers
83630	Lactoferrin, fecal; qualitative
83631	Lactoferrin, fecal; quantitative

V. CPT or HCPC codes NOT covered

Codes	Description
TPMT	
83789	Mass spectrometry and tandem mass spectrometry (e.g., MS, MS/MS, MALDI, MS-TOF, QROF), non-drug analyt(s), not elsewhere specified, qualitative or quantitative, each specimen
86256	Fluorescent noninfectious agent antibody; titer, each antibody
6-thioguanine nucleotide (6-TGN) and 6-methylmercaptopurine nucleotide (6-MMPN)	
80299	Quantification of therapeutic drug, not elsewhere specified
ACCA, ALCA, AMCA, Anti-C, Anti-L, ANCA, ASCA, OmpC, anti-Cbir-1, 12 antibodies, and ASMA	
82397	Chemiluminescent assay
83516	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen, qualitative or semi-quantitative; multiple step method
83518	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, single step method (eg, reagent strip)
83519	quantitative, by radioimmunoassay (eg, RIA)
83520	Immunoassay, analyte, quantitative; not otherwise specified
86021	Antibody identification; leukocyte antibodies [ANCA antibodies]
86255	Fluorescent noninfectious agent antibody; screen, each antibody
86671	Antibody; fungus, not elsewhere specified
88350	Immunofluorescence, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure)
ANSER IFX; ANSER ADA; ANSER VDZ; ANSER UST	
84999	Unlisted chemistry procedure
80299	Quantification of therapeutic drug, not elsewhere specified
83516	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen, qualitative or semi-quantitative; multiple step method
83520	Immunoassay, analyte, quantitative; not otherwise specified
86235	Extractable nuclear antigen, antibody to, any method (e.g., nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody [measurement of anti-histone antibodies for monitoring infliximab therapy]

VI. Annual Review History

Review Date	Revisions	Effective Date
05/2013	Annual Review: Added table with review date, revisions, and effective date. Revised criteria to include criteria for approval of TPMT testing.	05/2013

04/2014	Annual Review: Revised names of tests – added new tests from Prometheus considered E/I, added fecal calprotectin considered E/I	04/14
04/2015	Annual Review: Added test names from Prometheus and updated CPT codes covered and non-covered for each test.	04/25/2015
05/2016	Annual Review: Minor wording revisions – no change to criteria	05/25/2016
05/2017	Annual Review: Revised wording for the non-covered tests	05/24/2017
05/2018	Annual Review: Added language tests may be performed by labs other than Prometheus. Removed fecal calprotectin for children 12 and under – no literature to support	05/24/2018
04/2019	Annual review – no changes	05/01/2019
11/2019	Updates & review: Criteria reviewed and updated to reflect indications required for coverage of TPMT genetic testing for IBD. Updated the list of tests considered E&I, covered and non-covered codes	12/05/2019
07/2020	Annual Review: Fecal measurement of calprotectin is now considered for the management of inflammatory bowel diseases in addition to distinguishing inflammatory bowel disease from inflammatory bowel syndrome. Removed deleted code 82491	08/01/2020
07/31/2020	Update: added code 82542	
07/2021	Annual Review: No content change	08/01/2021
06/2022	Annual Review: No content change	07/01/2022
07/2023	Annual Review: No content change	08/01/2023
05/2024	Updates: Removed codes no longer requiring review	
06/26/2024	Annual Review: Removed requirements for Fecal measurement of calprotectin, prior authorization no longer required. added Prometheus IBD sgi diagnostic test	07/01/2024

VII. References

1. Anand V, Russell AS, Tsuyuki R, Fedorak R. Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies as serological markers are not specific in the identification of Crohn's disease and ulcerative colitis. *Can J Gastroenterol.* 2008 Jan;22(1):33-6.
2. Crohn's and Colitis Foundation of America website. Accessed on May 22, 2013, at: www.cdfa.org.
3. Differentiating between Crohn's disease and ulcerative colitis with anti-saccharomyces cerevisiae and anti-neutrophil cytoplasmic antibodies. May 2002. Accessed on May 22, 2013, at: www.aruplab.com
4. Dotan I. New serologic markers for inflammatory bowel disease diagnosis. *Dig Dis.* 2010;28(3):418-423.
5. Dubinsky M, Ofman J, Urman M, Targan S, Seidman E. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. *Am J Gastroenterol.* 2001 Mar;96(3):758-65.
6. Dubinsky MC, Lin YC, Dutridge D, Picornell Y, Landers CJ, Farris S, et al., for the Western Regional Pediatric IBD Research Alliance. Serum immune responses predict rapid disease progression

- among children with Crohn's disease: immune responses predict disease progression. *Am J Gastroenterol*. 2006 Feb;101(2):360-7.
7. Dubinsky MC, Reyes E, Ofman J, et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. *Am J Gastroenterol* 2005; 100:2239-47
 8. Gupta A, Derbes C, Sellin J. Clinical indications of the use of antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in the evaluation of inflammatory bowel disease at an academic medical center. *Inflamm Bowel Dis*. Oct 2005; 11(10):898-902.
 9. Hanauer SB, Sandborn W. Management of Crohn's disease in adults. *Am J Gastroenterol* March 2001; 96(3):635-43.
 10. Information provided by Prometheus Laboratories-IBD First Step, IBD Diagnostic System, Comparison of ANCA.
 11. Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. *Gut*. Sept 2005; 54(9):1232-6.
 12. Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: A prospective follow-up study. *Gastroenterology*. 2002; 122(5):1242-1247.
 13. Kornbluth and Sachar. The practice parameters committee of the American College of
 14. Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto-and microbial antigens. *Gastroenterology*. 2002; 123(3):689-99.
 15. Lichtenstein GR, Hanauer SB, Sandborn WJ; American College of Gastroenterology Clinical Practice Guideline: Management of Crohn's Disease; *Am J Gastroenterol*. 2009 Feb;104(2):465-83
 16. Linskens RK, Mallant-Hent RC, Groothuisink A, Bakker-Jonges LE, van de Merwe JP, Hooijkaas H, et al. Evaluation of serological markers to differentiate between ulcerative colitis and Crohn's disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods. *Eur J Gastroenterol Hepatol*. 2002 Sep 01;14(9):1013-18.
 17. Mokrowiecka A, Daniel P, Słomka M, et al. Clinical utility of serological markers in inflammatory bowel disease. *Hepato-gastroenterology*. 2009;56(89):162-166.
 18. Mow WS, Vasiliauskas EA, Ying-Chao L, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. *Gastroenterol*. 2004;126(2):414-424.
 19. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition; Colitis Foundation of America, Bousvaros A, Antonioli DA, Colletti RB, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: Report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. *J Pediatr Gastroenterol Nutr*. 2007;44(5):653-674.
 20. Overuse of serological testing for inflammatory bowel disease. *Mayo Clinic Communiqué*. September 2006;31(9).
 21. Peeters M, Joossens S, Vermeire S, et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. *American Journal of Gastroenterology*. March 2001; 96(3):730
 22. Reese GE, Constantinides VA, Simillis C, Darzi AW, Orchard TR, Fazio VW, et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. *Am J Gastroenterol*. 2006 Oct;101(10):2410-22. Epub 2006 Sep 4.
 23. Rutgeerts P, Vermeire S. Clinical value of the detection of antibodies in the serum for diagnosis and treatment of inflammatory bowel disease. *Gastroenterology*. 1998; 115(4):1006-1009.

24. Sabery N, Bass D. Use of serologic markers as a screening tool in inflammatory bowel disease compared with elevated erythrocyte sedimentation rate and anemia. *Pediatrics* 2007;119; e193-e199.
25. Saito H, Fukuda Y, Katsuragi K, et al. Isolation of peptides useful for differential diagnosis of Crohn's disease and ulcerative colitis. *Gut*. 2003 Apr; 52(4):535-40.
26. Vermeire S, Joossens S, Peeters M, et al. Comparative study of ASCA assays in inflammatory bowel disease. *Gastroenterology*. 2001; 120(4)827-833.
27. Physician Advisors

Appendix 1 - Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD):

Jurisdiction(s): 5, 8	NCD/LCD Document (s):

NCD/LCD Document (s):

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC